

**Course unit name: CLINICAL PHARMACOKINETICS OF ANTINEOPLASTIC DRUGS**

**1.- General information**

|                  |                         |   |           |             |                          |
|------------------|-------------------------|---|-----------|-------------|--------------------------|
| Code             | 303008                  | Plan  |           | ECTS        | 3                        |
| Type             | Elective                | Course  | 2026/2027 | Periodicity | 1 <sup>st</sup> Semester |
| Department       | Pharmaceutical Sciences |   |           |             |                          |
| Virtual Platform | Platform:               | Studium:  |           |             |                          |
|                  | URL de Acces:           | <a href="https://studium.usal.es/">https://studium.usal.es/</a> |           |             |                          |

**Faculty: Pharmacy**

|                       |   |       |                     |  |  |
|-----------------------|---|-------|---------------------|--|--|
| Professor coordinator | Amparo Sánchez Navarro  |       |                     |  |  |
| Department            | Pharmaceutical Sciences   |       |                     |  |  |
| Research area         | Pharmacy and Pharmaceutical Technology  |       |                     |  |  |
| Center                | Faculty of Pharmacy   |       |                     |  |  |
| URL Web               | <a href="https://produccioncientifica.usal.es/investigadores/56100/detalle">https://produccioncientifica.usal.es/investigadores/56100/detalle</a> |       |                     |  |  |
| E-mail                | <a href="mailto:asn@usal.es">asn@usal.es</a>  | Phone | 923294500. Ext:6744 |  |  |

|               |   |       |                         |  |  |
|---------------|---|-------|-------------------------|--|--|
| Professor     | Marina Holgado Madruga  |       |                         |  |  |
| Department    | Physiology and Pharmacology   |       |                         |  |  |
| Research area | Pharmacology  |       |                         |  |  |
| Center        | Faculty of Medicine   |       |                         |  |  |
| URL Web       | <a href="https://produccioncientifica.usal.es/investigadores/57867/detalle">https://produccioncientifica.usal.es/investigadores/57867/detalle</a> |       |                         |  |  |
| E-mail        | <a href="mailto:mholgado@usal.es">mholgado@usal.es</a>  | Phone | +34 923294500 (ext1488) |  |  |

|               |  |  |  |  |  |
|---------------|--|--|--|--|--|
| Professor     | José Germán Sánchez Hernández  |  |  |  |  |
| Department    | Pharmacy Service at the University Hospital of Salamanca<br>Pharmaceutical Sciences Department |  |  |  |  |
| Research area | Pharmacy and Pharmaceutical Technology   |  |  |  |  |
| Center        | University Hospital of Salamanca<br>Faculty of Pharmacy  |  |  |  |  |

|         |   |       |                              |
|---------|---|-------|------------------------------|
| URL Web | <a href="https://produccioncientifica.usal.es/investigadores/147958/publicaciones">https://produccioncientifica.usal.es/investigadores/147958/publicaciones</a> |       |                              |
| E-mail  | Jgermansanchez@salu<br>dcastillayleon.es  | Phone | +34 923291100<br>(ext 56051) |

|               |   |       |                          |
|---------------|---|-------|--------------------------|
| Professor     | Hinojal Zazo Gómez  |       |                          |
| Department    | Pharmaceutical Sciences   |       |                          |
| Research area | Pharmacy and Pharmaceutical Technology  |       |                          |
| Center        | Faculty of Pharmacy   |       |                          |
| URL Web       | <a href="https://produccioncientifica.usal.es/investigadores/107727/detalle">https://produccioncientifica.usal.es/investigadores/107727/detalle</a> |       |                          |
| E-mail        | <a href="mailto:hinojal@usal.es">hinojal@usal.es</a>  | Phone | +34 923294500 (ext 6762) |

## 2.- The course in the context of the Master's Program

|   |
|---|
| <b>Training Module</b>  |
| Thirth block (out of five) of master program organization.<br>See Academic Schedule   |
| <b>General aim of the subject</b>   |
| The objective of this subject is to review and apply the basic concepts of clinical pharmacokinetics (CPK) together with " <i>in silico</i> " and hospital tools for dosage optimization of drugs used for cancer diseases. Clinical PK contributes to the precision medicine in personalising drug dosages, according to patient characteristics. In addition, therapeutic drug monitoring (TDM) is addressed as a tool for dosage individualization to improve clinical outcomes in terms of efficacy and/or safety. Also physiologically based pharmacokinetic (PBPK) analysis is undertaken. All the above approaches are considered to implement model informed precision dosing (MIPD) in oncotherapy |
| <b>Professional specialization</b>  |
| This topic is oriented to researchers and clinicians involved in clinical investigation, drug development and improvement of using antineoplastic drugs in clinical practice. These include Pysisicians, Pharmacists, Biotechnologists, Biologists, and other professionals integrated in multidisciplinary groups working on optimization of pharmacological treatment of cancer.  |

## 3.- Previous recommendations

A degree on life sciences topics.

#### 4.- Aims of the subject

To provide theoretical and practical knowledge about antineoplastic drugs oriented to the study of its pharmacokinetics (PK) and the main factors responsible for PK variability.

To acquire the ability to apply modeling and simulation tools, as well as TDM practice, to consider PK variability for the selection of precision dosages in the clinical practice.

##### Specific aims:

- To know the mechanism of action of the main antineoplastic drugs used in the clinical practice
- To understand the population pharmacokinetic (PopPK) modeling and simulation methodology and the factors with a relevant impact on patient exposure to drugs (demographics, physiopathological, genetics, etc.)
- To study the concepts and tools regarding TDM of antineoplastic drugs in the clinical routine
- To learn about physiological based pharmacokinetic (PBPK) modeling and simulations approach and its application to *in silico* clinical trials
- To achieve a holistic knowledge on the operation in a hospital pharmacy service for development, validation and follow-up of oncological therapies

#### 5.- Contents

##### TOPICS (LECTURES):

1. Mechanism of action of the main anticancer drugs used in clinical practice
2. Clinical pharmacokinetics: basic concepts and application to antineoplastic drugs
3. Population pharmacokinetics (PopPK)
4. Physiological Based Pharmacokinetic (PBPK) analysis
5. Model-informed precision dosing and follow-up criteria in oncology treatments

##### SEMINARS and HANDS-ON:

1. Data handling and Bayesian estimation
2. Implementation of population pharmacokinetic models
3. Parameters estimation of antineoplastic drugs: case reports
4. Application of PBPK models to oncology patients
5. *In silico* clinical trials
6. Development and validation of the oncology therapy in a hospital pharmacy service

#### 6.- Skills to be acquired

##### Basic skills

Understanding the usefulness of clinical PK to evaluate factors with a significant impact on the response to pharmacological treatments

Application of PK tools for dosage individualization in the oncological patient

Ability to use the PopPK models to improve the efficacy and safety of treatments with antineoplastic drugs

Application of PBPK models for "first-in-human" dose estimation and dosage individualization in oncologic patients

Pharmacy validation and follow-up of oncological therapies in a University Hospital

##### Specific skills

- Interpretation and application of TDM results to optimize and individualize pharmacological treatments with antineoplastic drugs

- Using pharmacokinetic information to select the dosage regimen with the optimal benefit/risk ratio for antineoplastic drugs
- Ability to use software for performing clinical trials in virtual populations
- Understanding the application of PBPK models for dosage optimization
- Understanding the multidisciplinary of the clinical team involved in the validation and follow-up of onco-hematologic therapies

## 7.- Teaching methodology

- Introductory activity
- Lectures
- Seminars
- Hands-on
- Case reports discussions
- Focused activities: presentation, analysis and proposals related to scientific papers

## 8.- Estimated learning time

|                                |                           | Hours tutored by the teacher |                           | Individual work (hours) | TOTAL HOURS |
|--------------------------------|---------------------------|------------------------------|---------------------------|-------------------------|-------------|
|                                |                           | Attendance required (hours)  | Distance learning (hours) |                         |             |
| Lectures                       |                           | 11                           | 8                         | 10                      | 29          |
| Practices                      | - In classroom            |                              |                           |                         |             |
|                                | - In laboratory           |                              |                           |                         |             |
|                                | - In computer classroom   | 6                            |                           |                         | 6           |
|                                | - Countryside             |                              |                           |                         |             |
|                                | - Visualization classroom |                              |                           |                         |             |
| Seminars                       |                           | 4                            |                           | 2                       | 6           |
| Work presentations and debates |                           | 7                            |                           | 8                       | 15          |
| Tutorials                      |                           | 2                            |                           | 2                       | 4           |
| Online activities              |                           |                              |                           |                         |             |
| Work preparation               |                           |                              | 5                         | 7                       | 12          |
| Other activities               |                           | 3                            |                           |                         | 3           |
| <b>TOTAL</b>                   |                           | <b>33</b>                    | <b>13</b>                 | <b>29</b>               | <b>75</b>   |

## 9.- Materials

### Books

Individualizing Dosage Regimens of Antineoplastic Agents. In Individualized Drug Therapy for Patients: Basic foundations, Relevant software and clinical applications. Ed. Jelliffe R and Neely M. Elsevier. 281-306, 2017.

A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne:  
<http://www.boomer.org/c/p4/>

### Scientific Journals

- Therapeutic Drug Monitoring

- Clinical Pharmacokinetics
- British Journal of Clinical Pharmacology

Recommended lecture

- Veal GJ, et al. (2019) Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. *Ther Drug Monit*;41:142–159.
- Guidi M, et al (2020). Parametric Approaches in Population Pharmacokinetics. *J Clin Pharmacol*. Oct 26. doi: 10.1002/jcph.1633. Epub ahead of print. PMID: 33103774. <https://doi.org/10.1002/jcph.1633>
- Darwich, A. S. et al. (2021). Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. *Annual Review of Pharmacology and Toxicology*, 61(1), 225–245. <https://doi.org/10.1146/annurev-pharmtox-033020-113257>
- Mueller-Schoell A. et al. (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. *European Journal of Clinical Pharmacology* 77:441–464. <https://doi.org/10.1007/s00228-020-03014-8>
- Guenka Petrova, Stiliyana Blagova, Konstantin Tachkov, Marlene Santos, James Bluett, Merita Rumano, Elena Kkolou, Elena Drakalska, Marija Arev, Mehtap Cakmak Barsbay, Denis Mulleman (2025). Therapeutic drug monitoring education: The current state. <https://doi.org/10.1002/bcp.70252>

## 10.- Assessment

### Assessments on the performance of the student

Continuous follow-up of the knowledge, skills and abilities acquired by the students.  
Student participation will be highly appreciated and positively taken into account.  
Attendance and active participation in lectures and seminars (hands-on).  
Comments and proposals to the case-studies  
Scientific accuracy of the commentaries and answers to the questions and debates during lectures and seminars  
Presentation and debate of a scientific paper

### Recommendations

Active participation in the proposed activities  
Debate about the multidisciplinary nature of the optimization of oncological treatments.